{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:32:39Z","timestamp":1795026759716,"version":"4.10.2"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computers in Biology and Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.compbiomed.2025.111204","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T03:01:32Z","timestamp":1760497292000},"page":"111204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"PA","title":["Design, synthesis, and evaluation of novel quinazoline derivatives as potent EGFR inhibitors: In silico and in vitro approaches"],"prefix":"10.1016","volume":"198","author":[{"given":"Mohamed J.","family":"Saadh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara Nazar","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karar H.","family":"Alfarttoosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Kakkad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subbulakshmi","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Shankhyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sunitha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafar","family":"Aminov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waam","family":"Mohammed Taher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariem","family":"Alwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6542-7230","authenticated-orcid":false,"given":"Mahmood Jasem","family":"Jawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali M.Ali","family":"Al-Nuaimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.compbiomed.2025.111204_bib1","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.cellsig.2007.06.023","article-title":"Mechanisms for oncogenic activation of the epidermal growth factor receptor","volume":"19","author":"Zandi","year":"2007","journal-title":"Cell. Signal."},{"key":"10.1016\/j.compbiomed.2025.111204_bib2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/08977190802312844","article-title":"EGFR family: structure physiology signalling and therapeutic targets","volume":"26","author":"Burgess","year":"2008","journal-title":"Growth Factors"},{"key":"10.1016\/j.compbiomed.2025.111204_bib3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/annonc\/mdq432","article-title":"EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer","volume":"22","author":"Dahabreh","year":"2011","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.compbiomed.2025.111204_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19020408","article-title":"The design and development of potent small molecules as anticancer agents targeting EGFR TK and tubulin polymerization","volume":"19","author":"Ihmaid","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.compbiomed.2025.111204_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.compbiomed.2025.111204_bib6","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s10350-004-6756-1","article-title":"Reduced survival of rectal cancer patients with increased tumor epidermal growth factor receptor levels","volume":"46","author":"Kopp","year":"2003","journal-title":"Dis. Colon Rectum"},{"key":"10.1016\/j.compbiomed.2025.111204_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032651","article-title":"Small molecule EGFR inhibitors as anti-cancer agents: discovery, mechanisms of action, and opportunities","volume":"24","author":"Zubair","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.compbiomed.2025.111204_bib8","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.tips.2019.10.004","article-title":"A third shot at EGFR: new opportunities in cancer therapy","volume":"40","author":"Guardiola","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.compbiomed.2025.111204_bib9","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.compbiomed.2025.111204_bib10","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s43094-021-00279-3","article-title":"Design of more potent quinazoline derivatives as EGFRWT inhibitors for the treatment of NSCLC: a computational approach","volume":"7","author":"Ibrahim","year":"2021","journal-title":"Futur. J. Pharm. Sci."},{"key":"10.1016\/j.compbiomed.2025.111204_bib11","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.ejmech.2008.09.015","article-title":"Substituted quinazolines, part 3. Synthesis, in vitro antitumor activity and molecular modeling study of certain 2-thieno-4(3H)-quinazolinone analogs","volume":"44","author":"Al-Obaid","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.compbiomed.2025.111204_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19061731","article-title":"Design, synthesis, cytotoxic evaluation and molecular docking of new fluoroquinazolinones as potent anticancer agents with dual EGFR kinase and tubulin polymerization inhibitory effects","volume":"19","author":"Zayed","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.compbiomed.2025.111204_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrep.2024.101745","article-title":"Development of an ancestral DC and TLR4-inducing multi-epitope peptide vaccine against the spike protein of SARS-CoV and SARS-CoV-2 using the advanced immunoinformatics approaches","volume":"39","author":"Aram","year":"2024","journal-title":"Biochem. Biophys. Reports."},{"key":"10.1016\/j.compbiomed.2025.111204_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e30898","article-title":"Matrix metalloproteinase\/Fas ligand (MMP\/FasL) interaction dynamics in COVID-19: an <em>in silico<\/em> study and neuroimmune perspective","volume":"10","author":"Saleki","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.compbiomed.2025.111204_bib15","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures","volume":"58","author":"V Pires","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.compbiomed.2025.111204_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2025.107691","article-title":"Decoding virulence and resistance in Klebsiella pneumoniae: pharmacological insights, immunological dynamics, and in silico therapeutic strategies","author":"Alishvandi","year":"2025","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.compbiomed.2025.111204_bib17","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1038\/s41598-022-11641-7","article-title":"Modelling liver cancer microenvironment using a novel 3D culture system","volume":"12","author":"Al Hrout","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.compbiomed.2025.111204_bib18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.14715\/cmb\/2024.70.11.21","article-title":"Assessment of decreased ovarian reserve and systemic inflammatory markers","volume":"70","author":"Shoarishoar","year":"2024","journal-title":"Cell. Mol. Biol."},{"key":"10.1016\/j.compbiomed.2025.111204_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1399372","article-title":"Deciphering quinazoline derivatives' interactions with EGFR: a computational quest for advanced cancer therapy through 3D-QSAR, virtual screening, and MD simulations","volume":"15","author":"Anwar","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.compbiomed.2025.111204_bib20","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/1878-0261.12556","article-title":"Improving the efficacy of osteosarcoma therapy: combining drugs that turn cancer cell \u201cdon't eat me\u201d signals off and \u201ceat me\u201d signals on","volume":"13","author":"Mohanty","year":"2019","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.compbiomed.2025.111204_bib21","first-page":"479","article-title":"In vitro assessment of paclitaxel-loaded niosome nanoparticles and their cytotoxic effects on the ovarian cancer cell line A2780CP, Asia Pacific","volume":"9","author":"Khaje","year":"2024","journal-title":"J. Cancer Biol."},{"key":"10.1016\/j.compbiomed.2025.111204_bib22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.str.2012.11.014","article-title":"Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition","volume":"21","author":"Gajiwala","year":"2013","journal-title":"Structure"},{"key":"10.1016\/j.compbiomed.2025.111204_bib23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.14715\/cmb\/2024.70.11.16","article-title":"Comparison of pregnancy outcomes in amniocentesis recipients with normal and abnormal maternal serum analytes","volume":"70","author":"Shoarishoar","year":"2024","journal-title":"Cell. Mol. Biol. (Noisy-Le-Grand)."},{"key":"10.1016\/j.compbiomed.2025.111204_bib24","doi-asserted-by":"crossref","first-page":"8103","DOI":"10.1021\/acs.jmedchem.6b00883","article-title":"Tyrosine kinase inhibitors. 20. Optimization of substituted quinazoline and Pyrido[3,4-d]pyrimidine derivatives as orally active, irreversible inhibitors of the epidermal growth factor receptor family","volume":"59","author":"Smaill","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.compbiomed.2025.111204_bib25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.fitote.2017.05.001","article-title":"Pharmaceutical prospects of naturally occurring quinazolinone and its derivatives","volume":"119","author":"He","year":"2017","journal-title":"Fitoterapia"},{"key":"10.1016\/j.compbiomed.2025.111204_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113778","article-title":"Discovery of quinazoline derivatives as a novel class of potent and in vivo efficacious LSD1 inhibitors by drug repurposing","volume":"225","author":"Li","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.compbiomed.2025.111204_bib27","article-title":"Investigating body dysmorphic disorder in pregnant mothers requesting cesarean section","author":"Alimi","year":"2024","journal-title":"J. Obstet. Gynecol. Cancer Res."},{"key":"10.1016\/j.compbiomed.2025.111204_bib28","doi-asserted-by":"crossref","first-page":"105479","DOI":"10.18632\/oncotarget.22297","article-title":"Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations","volume":"8","author":"Masuzawa","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.compbiomed.2025.111204_bib29","doi-asserted-by":"crossref","first-page":"38789","DOI":"10.18632\/oncotarget.5887","article-title":"In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer","volume":"6","author":"Hirano","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.compbiomed.2025.111204_bib30","doi-asserted-by":"crossref","DOI":"10.24200\/jogcr.10.11.843","article-title":"A cross-sectional investigation of sleep health and disorders in women with polycystic ovary syndrome","author":"Saranjam","year":"2025","journal-title":"J. Obstet. Gynecol. Cancer Res."},{"key":"10.1016\/j.compbiomed.2025.111204_bib31","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jphp.12928","article-title":"Impact of gastrointestinal disease states on oral drug absorption \u2013 implications for formulation design \u2013 a PEARRL review","volume":"71","author":"Effinger","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.compbiomed.2025.111204_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.humgen.2025.201390","article-title":"Epidermal growth factor receptor (EGFR) as a key regulator in type 2 diabetes: drug discovery insights","volume":"43","author":"Ochoa","year":"2025","journal-title":"Hum. Gene."},{"key":"10.1016\/j.compbiomed.2025.111204_bib33","doi-asserted-by":"crossref","first-page":"8885","DOI":"10.1038\/s41598-023-33065-7","article-title":"Discovery of the allosteric inhibitor from actinomyces metabolites to target EGFRCSTMLR mutant protein: molecular modeling and free energy approach","volume":"13","author":"Saini","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.compbiomed.2025.111204_bib34","doi-asserted-by":"crossref","DOI":"10.1111\/jog.16316","article-title":"The efficacy of intraovarian versus subcutaneous corifollitropin alfa administration in DuoStim protocol for infertile women with low in vitro fertilization response","volume":"51","author":"Keikha","year":"2025","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"10.1016\/j.compbiomed.2025.111204_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrep.2025.102135","article-title":"The HER2 target for designing novel multi-peptide vaccine against breast cancer using immunoinformatics and molecular dynamic simulation","volume":"43","author":"Firuzpour","year":"2025","journal-title":"Biochem. Biophys. Reports."},{"key":"10.1016\/j.compbiomed.2025.111204_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-80946-6","article-title":"Development of a novel gut microphysiological system that facilitates assessment of drug absorption kinetics in gut","volume":"14","author":"Imaoka","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.compbiomed.2025.111204_bib37","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/17460441.2023.2211801","article-title":"Promising strategies for improving oral bioavailability of poor water-soluble drugs","volume":"18","author":"Rocha","year":"2023","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.compbiomed.2025.111204_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.145203","article-title":"Unveiling the translational and therapeutic potential of small interfering RNA molecules in combating SARS-CoV-2: a review","author":"Aram","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.compbiomed.2025.111204_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.jscs.2023.101597","article-title":"Synthesis of Quinazolin-4(3H)-ones via a novel approach","volume":"27","author":"Akbari","year":"2023","journal-title":"J. Saudi Chem. Soc."},{"key":"10.1016\/j.compbiomed.2025.111204_bib40","first-page":"1048","article-title":"Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations","volume":"5","author":"Yeo","year":"2010","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer."},{"key":"10.1016\/j.compbiomed.2025.111204_bib41","first-page":"109","article-title":"Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy","volume":"8","author":"Santarpia","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.compbiomed.2025.111204_bib42","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1158\/1535-7163.MCT-08-0168","article-title":"Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells","volume":"7","author":"Zhang","year":"2008","journal-title":"Mol. Cancer Therapeut."}],"container-title":["Computers in Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482525015574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482525015574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:43:38Z","timestamp":1780548218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010482525015574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":42,"alternative-id":["S0010482525015574"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiomed.2025.111204","relation":{},"ISSN":["0010-4825"],"issn-type":[{"value":"0010-4825","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and evaluation of novel quinazoline derivatives as potent EGFR inhibitors: In silico and in vitro approaches","name":"articletitle","label":"Article Title"},{"value":"Computers in Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiomed.2025.111204","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111204"}}